ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

Authors

Sandra P. D'Angelo

Memorial Sloan Kettering Cancer Center, New York, NY

Sandra P. D'Angelo , Steven Ian Robinson , Joelle Lam , Bonne J. Adams , James L. Freddo , Charles P. Theuer , Robert G Maki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

First Author: Richard F. Riedel

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.

First Author: Lorenzo Pilla

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

First Author: Sylvie Lorenzen

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.

First Author: Josep Tabernero